CoChat

Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme

Open access
Samalin, Ludovic, Rothärmel, Maud, Mekaoui, Lila, Gaudré-Wattinne, Emeline, Codet, Marie-Alix, Bouju, Sophie, Sauvaget, Anne · 2022 · International Journal of Psychiatry in Clinical Practice

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To present the first real-world data of patients with treatment-resistant depression (TRD) treated with esketamine through a French cohort Temporary Authorisation for Use (ATUc) programme. METHODS: In 2019, the French Health Authorities exceptionally granted the first ATUc in psychiatry for TRD patients. Clinical characteristics, safety and efficacy data were reported by physicians. The ATUc ended ∼6 months after initiation. RESULTS: = 66; median age 53.0 years; 62.1% female; 78.8% with severe major depressive episodes; resistance to a mean of 4.2 previous antidepressants) received esketamine treatment for a median of 30 days. Among 46 analysed patients, 22 (47.8%) achieved response (Montgomery-Åsberg Depression Rating Scale [MADRS] total score reduction ≥50.0%) and 17 (37.0%) achieved remission (MADRS total score of ≤12) at least once at a median of 18.5 (2.0-77.0) and 21.0 (2.0-46.0) days after initiation, respectively. By Week 4, patients had a 31.6% probability of achieving remission (Kaplan-Meier method). Sedation, somnolence, dizziness, hypertension, anxiety and dissociation were the most frequently reported (>10.0%) adverse events. No new safety signals were identified. CONCLUSIONS: Patient characteristics of this cohort demonstrate high-level treatment resistance. The safety and efficacy of esketamine in patients with TRD in real-world clinical practice were consistent with Phase 3 trials.Key pointsPatients with treatment-resistant depression (TRD) exceptionally received esketamine nasal spray ahead of its launch through a French cohort Temporary Authorisation for Use (ATUc) programme.The clinical characteristics of 66 adult patients with TRD included in this cohort demonstrated a high-level of resistance to conventional treatments at the time of treatment request prior to esketamine initiation.No new safety signals were observed with esketamine initiation during the ATUc period compared with the Phase 3 clinical trials.The safety and efficacy of esketamine in the real world remain consistent with that established in Phase 3 clinical trials.The data collected during this ATUc also provide the first real-world data on the management and practical use of esketamine in a hospital setting in France.

Overview

Integrity signals

Registry

Crossref · 10.1080/13651501.2022.2030757

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 2

  1. Léon C, 2018, Bull Epidémiol Hebd, 32, 637
  2. Thase ME, 1997, J Clin Psychiatry, 58, 23

Cited by

See all 54

Metadata

Authors
Samalin, L., Rothärmel, M., Mekaoui, L., Gaudré-Wattinne, E., Codet, M.-A., Bouju, S., & Sauvaget, A.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Centre Hospitalier du Rouvray (FR)
  • Mental and Brain Illness Clinic, Sainte-Anne Hospital, GHU Paris – Psychiatry and Neurosciences, Paris, France
  • Medical Affairs, Janssen-Cilag, Issy-les-Moulineaux, France
  • Janssen (France) (FR)
  • Centre Hospitalier Universitaire de Nantes (FR)
Corresponding author
Samalin, Ludovic
Venue
International Journal of Psychiatry in Clinical Practice
Published
2022-02-17
Volume
26
Issue
4
Pages
352-362
ISSN
  • 1365-1501 (ISSN-L)
  • 1471-1788
OpenAlex
W4213247170
Cited by
54
References
40
Citations by year
2026: 9 · 2025: 11 · 2024: 17 · 2023: 14 · 2022: 3
FWCI
6.73
Type
journal article
Language
en
Open access
Locations
  • International Journal of Psychiatry in Clinical Practice (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • HAL (submittedVersion, cc-by-nc-nd)
Funders
Janssen-Cilag
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
esketamine, nasal spray, treatment-resistant depression, major depressive disorder, real-world data, antidepressant resistance, treatment response and remission, adverse events, dissociation, sedation, hypertension, French cohort, drug safety and efficacy, early access program
MeSH terms
Administration, Intranasal, Adult, Depression, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Nasal Sprays, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. https://app.cochat.ai/papers/10.1080/13651501.2022.2030757
The paper
Samalin, L., Rothärmel, M., Mekaoui, L., Gaudré-Wattinne, E., Codet, M.-A., Bouju, S., & Sauvaget, A. (2022). Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651501.2022.2030757

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.